Latest News | Zydus Lifesciences Gets USFDA Nod to Produce Prostate Cancer Treatment Drug
Get latest articles and stories on Latest News at LatestLY. Zydus Lifesciences Ltd on Tuesday said it has received final approval from the US health regulator to manufacture a generic version of Apalutamide tablets used in the treatment of prostate cancer.
New Delhi, Mar 18 (PTI) Zydus Lifesciences Ltd on Tuesday said it has received final approval from the US health regulator to manufacture a generic version of Apalutamide tablets used in the treatment of prostate cancer.
The approval by the US Food and Drug Administration (USFDA) is to manufacture Apalutamide tablets of 60 mg strength, Zydus Lifesciences said in a regulatory filing.
The approved Apalutamide tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad, it added.
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.
Also Read | 7th Pay Commission: AICPI-IW Drops 0.5 Points Before Expected DA Hike for Central Govt Employees.
It had annual sales of USD 1,099.8 million in the US, the company said, citing IQVIA MAT January 2025 data.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)